Enrica Alteri

Dr Enrica Alteri is a MD, with a post-doctoral at the National Cancer Institute in USA and a diploma in Pharmaceutical Medicine.

Dr Alteri spent 13 years at Ciba-Geigy/Novartis, involved in major projects that yielded Gleevec for myeloid leukaemia, Coartem for malaria and Reyataz for HIV-AIDS. She led the Pharmacovigilance and Risk Management team at Serono for 14 years.

In 2012 she joined EMA, as Head of the Human Medicines Evaluation Division,  later Head of the Human Medicines R&D Support Division, and member of the Executive Board until 2020.  In these roles, she was part of many high impact initiatives (e.g. transparency of clinical trial data, development of regulatory science strategy to 2025).

Dr Alteri consulted for Swissmedic, and is currently member of the Scientific Committee and faculty of the Master in Drug R&D of the University of Geneva. Dr Alteri gives university lectures on various regulatory aspects of R&D. She is member of the CIOMS Working Group XIII (Real World Data/Real World Evidence), and the CIOMS Working Group Education. Most recently, she has been appointed as Core Member of the Proposal Review Committee of Unitaid.